Several lines of evidence implicate dopa decarboxylase (DDC) with schizophrenia. By analysis of two putative functional DDC variants in 173 schizophrenic patients and 204 controls we tested the hypotheses that DDC is involved in: (1) predisposition to schizophrenia; and (2) modulation of age at disease onset. No association was observed with schizophrenia as a whole, whereas an association between DDC genotypes and age at disease onset was suggested in males (P = 0.03). This association was most pronounced in relation to genotypes of haplotypes comprising both variants, suggesting an additive model where one variant mediates early and the other late onset. Accordingly, the haplotypebased genotypes could be assigned into three groups by their possible relative effect on age at onset: an 'early', 'neutral' and 'late' group. Dividing the male schizophrenics into four groups with increasing age at onset, the 'early' genotypes were seen to decrease in frequency from 51.5% to 16.7% while the 'late' genotypes increased from 12.1% to 33.3% (P = 0.02). The difference in mean age at onset between male patients with 'early' genotypes vs patients with 'late' genotypes was close to 5 years (95% CI: 0.7-8.8). Thus, DDC may possibly act as a modulator of age at onset in male schizophrenics. Molecular Psychiatry (2001) 6, 712-717.
The involvement of dopamine and dopaminergic pathways in the pathogenesis of schizophrenia has been a prevailing hypothesis for decades. 1 During the last few years, a more complex picture has emerged in which several neurotransmitters and neuromodulators may act as etiologic or modulating factors, possibly during the early stages of neurodevelopment.
2,3 Dopa decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a regulated enzyme required for the synthesis of dopamine and norepinephrine as well as serotonin. 4 In addition, DDC is rate limiting in the production of the trace amines 2-phenylethylamine (2-PE), p-tyramine, and tryptamine which are thought to act as neuromodulators.
DDC activity and 2-PE concentrations were found to be increased in, respectively, the brains and plasma of schizophrenics. [5] [6] [7] Recently, it has been shown that the two non-dopaminergic psychotogenic drugs, lysergic acid diethylamide (LSD) and phencyclidine (PCP), upregulate DDC mRNA levels in specific areas of the rat brain supporting the hypothesis that overactivity of DDC is involved in the development of psychosis such as schizophrenia. 8 There is also evidence pointing at a possible specific involvement of dopaminergic neurotransmission in determining the age at onset of schizophrenia. Numerous studies have found that the onset of schizophrenia for females is later than that for males, 9 and this has been suggested to be due to the influence of estrogen on dopaminergic neurotransmission. 10 Given the evidence outlined above, DDC is an interesting candidate gene for susceptibility to schizophrenia and for influencing age at disease onset. Recently, we identified two sequence variants in the DDC gene with putative functional impact on the level of gene expression: a 1-bp deletion located in the neuronal promoter and a 4-bp deletion located in the untranslated neuronal exon 1. 11 In the same study, evidence was obtained suggesting that the 1-bp deletion may confer an increased risk for development of bipolar affective disorder while no effect was associated with the 4-bp deletion. More recently, a case-control study examining only the 4-bp deletion variant in schizophrenia reported no significant association. 12 By analysis of both of the two DDC variants in a Scottish sample of 173 schizophrenics and 204 controls we tested the hypotheses that: (1) DDC can act as a susceptibility gene for schizophrenia; and (2) can modulate age at onset in schizophrenia.
Allele and genotype distributions of the two DDC variants showed no significant differences between schizophrenic patients and controls (P-values ranging from 0.447 to 0.894). No significant deviations from Hardy-Weinberg equilibrium were observed for any of the two variants in either the patient or the control samples. Nor were any significant associations found when analyzing the 45 patients with positive family history separately, or when analyzing each gender separately. Thus, in accordance with previous results obtained by analysis of only the 4-bp deletion variant, 12 we found no support for the hypothesis that DDC should be involved in susceptibility to schizophrenia.
The frequencies of both deletions in the patient and control samples were similar to the frequencies observed in Danish and English populations. 11 As in Danish and English populations, the 1-bp deletion was found to be in complete linkage disequilibrium with the wildtype allele of the 4-bp deletion variant. Using the EH program, 13 the normalized linkage disequilibrium coefficient DЈ was calculated to be −1.00 with a high degree of confidence ( 2 = 25.63, df = 1, P Ͻ 10
−6
). This means that the haplotype comprising both deletions probably does not exist. Consistent herewith we have not seen this haplotype in a Caucasian family material comprising more than 230 trios (unpublished results). Thus, the three existing haplotypes include A (1-bp deletion, wildtype of the 4-bp deletion variant), B (4-bp deletion, wildtype of the 1-bp deletion variant), and C (wildtypes of both variants), giving rise to six possible genotypic combinations referred to as haplotype-based genotypes.
To test the second hypothesis that DDC may influence the age at disease onset we examined the two variants in the 153 cases informative with respect to age at onset. Dividing the patients into two groups according to the median age at onset, a significant difference in the genotypic distribution of the 1-bp deletion variant was observed (Table 1 , P = 0.028), suggesting a late onset effect of the 1-bp deletion. An opposite effect of the 4-bp deletion was indicated, although not statistically significant (Table 1) .
Assuming an additive effect of the variants on age at disease onset, the six existing haplotype-based genotypes can be ordered according to the apparently opposite effects of the two variants, assigning the 'early' haplotype-based genotype BB at one end and the 'late' AA at the other end (Table 1) . Since the effect of the 1-bp deletion variant was more significant than the 4-bp deletion variant on the simple genotypic level, the AB genotype comprising both variants was assigned to the right ('late') side of the wildtype ('neutral') CC genotype. Analyzing this ordered distribution in the groups of early and late onset, a difference was observed (Table 1 , P = 0.044) suggesting that age at onset might depend on specific DDC genotypes of haplotypes comprising both of the variants.
It has repeatedly and almost consistently been reported that males have an earlier onset than females. 9 A similar, yet statistically insignificant, tendency was observed in the present patient sample. We therefore investigated the influence of DDC on age at onset in each sex separately. In males, the frequency of the 1-bp deletion increased steadily from 8% in patients with age at onset Ͻ20 years to 17% in patients with age at onset Ն40 years. Dividing the male patients according to the median age at onset, a preponderance of the 1-bp deletion was observed in the late onset group, examining the allele distribution ( 2 = 4.08, df = 1, P = 0.044), and the genotype distribution (Wilcoxon Rank-sum Test comparing all three genotypes, P = 0.029; 2 -test comparing genotypes with and without the deletion, 2 = 5.08, df = 1, P = 0.024). The reverse tendency (not significant) was observed for the Molecular Psychiatry 4-bp deletion decreasing evenly from 32% in patients with age at onset Ͻ20 years to 17% in patients with age at onset Ն40 years. In females the allele frequencies of both variants fluctuated inconsistently with increasing age at onset.
The changes in allele frequencies of the two variants were also reflected in the distribution of haplotypebased genotypes as presented in Table 2 . As mentioned above, the haplotype-based genotypes can be ordered by their specific content of the two variants, reflecting the apparently opposite effects of the two deletions (Table 1 ). In accordance with this order the haplotypebased genotypes can be arranged into three groups: (1) an 'early' group consisting of BB and BC; (2) a 'neutral' group comprising only CC; and (3) a 'late' group consisting of AB, AC, and AA. Thus, in this model the wildtype haplotype, C, is recessive in relation to both of the deletion haplotypes, A and B, and the 4-bp deletion haplotype, B, is recessive in relation to the dominant 1-bp deletion haplotype, A. Dividing the male patients into four groups according to their age at onset, a difference was observed between the 'early' group of haplotype-based genotypes (BB, BC) vs the 'late' group (AA, AB, AC) ( Table 2 , P = 0.020). With increasing age at onset the 'early' group was seen to decrease in frequency from 51.5% to 16.7% while the 'late' group increased in frequency from 12.1% to 33.3% (Table 2) . In this analysis it should also be noticed that genotypes with the 4-bp deletion and not the 1-bp deletion were found associated with earlier onset (Table 2 , P = 0.034). In the total sample the same trends were seen less significantly while the females showed no unambiguous trends in the distributions. These relations between DDC genotypes and age at onset are illustrated in Figure 1 , showing the cumulative morbidity as a function of age and the three groups of haplotype-based genotypes. The difference observed in males between the 'early' and 'late' group is clearly visualized, whilst the females show almost identical curves.
Another informative way to analyze the effects is from the inverted perspective examining the distribution of age at onset in relation to specific genotypes. Male patients carrying the 1-bp deletion showed a later onset than males without the 1-bp deletion (Table 3 , non-parametric P = 0.034, parametric P = 0.043). The difference in mean age at onset was 4 years (95% CI: 0.1-7.9). Conversely, male patients carrying the 4-bp deletion and not the 1-bp deletion had mean age of onset 2.7 years earlier than the other male patients, but this difference was not statistically significant. Comparing the groups of haplotype-based genotypes, a difference in mean age at onset of almost 5 years (95% CI: 0.7-8.8) was observed between males with the 'early' haplotype-based genotypes vs males with the 'late' haplotype-based genotypes (Table 3 , non-parametric P = 0.019, parametric P = 0.022). As expected, the females showed very similar distributions and mean ages at onset in the three groups. Furthermore, using linear regression to analyze the male age at onset distributions in relation to the haplotype-based genotypes, a 
Figure 1
Cumulative morbidity as a function of age and groups of haplotype-based genotypes illustrated in the total sample and in each gender separately. The red curves relate to the 'early' group of haplotype-based genotypes, the green curves relate to the 'neutral' group, and the blue curves relate to the 'late' group. The graphs visualize the difference observed in age at onset in males (and in the total sample) between patients with 'early' genotypes vs patients with 'late' genotypes (Table 2 ).
significant correlation was observed. This was the case when ordering the haplotype-based genotypes in the three groups (BB, BC)-(CC)-(AA, AB, AC) (P = 0.029), but also when dividing into more groups such as (BB)-(BC)-(CC)-(AA, AB, AC) (P = 0.018), and (BB)-(BC)-(CC)-(AB)-(AA,AC) (P = 0.042). When the AA and AC genotypes were separated, the correlation was no longer significant (P = 0.074) probably due to the very low number of male AA genotypes (only 2). Thus, the linear regression analysis indicates that the assignment of haplotype-based genotypes into three groups might be too crude-at least concerning the 'early' group. However, a powerful analysis of the effects of each single haplotype-based genotype would require a larger patient sample. We have obtained evidence suggesting that DDC genotypes may possibly influence age at onset specifically in males, and that this effect may depend on haplotypes comprising both variants examined. However, the association results reported in this study are not statistically very strong, representing some degree of multiple testing and should therefore be interpreted with caution. The tests are not independent, though, and it would be too conservative to apply a Bonferroni correction. Rather, the results presented should be regarded as a generation or refinement of hypothesis.
The apparent lack of effect of DDC genotypes on age at onset in females could be explained by female sex steroids inducing a negative effect on dopaminergic neurotransmission, 10 dominating the effects of the DDC variants. Considering the involvement of DDC in serotonin biosynthesis, it is interesting that differences in the responses of male and female schizophrenic patients to serotonergic challenge drugs have been reported. 14 In males, the results presented suggest a late onset effect of DDC genotypes containing the 1-bp deletion whereas genotypes containing the 4-bp deletion (and not the 1-bp deletion) were associated with early onset. Moreover, analysis of the haplotype-based genotype distribution in Table 1 and linear regression analysis suggested a dose-related correlation. In these analyses the BB genotype containing two copies of the 4-bp deletion was associated with the earliest onset, followed by BC containing only one copy of the 4-bp deletion, and CC containing only wildtype alleles. The 1-bp deletion seemed to mediate a dominant effect over the 4-bp deletion in the haplotype-based genotype comprising both variants (AB), as AB was associated with a protective effect stronger than CC. We have previously reported that both deletions affect binding sites for specific transcription factors in a way that may eliminate or impair the binding capacity, with a resulting impact on the level of expression.
11 Thus, the dose-related additive model of the haplotype-based genotypes described above appears meaningful in a biological context.
Early onset has been associated with poor response to neuroleptic treatment [15] [16] [17] [18] and worse long-term outcome. 19, 20 Häfner et al 1989 21 found that, specifically for men, symptom severity decreased with later onset. In males: (a) vs (c) testing non-parametrically using Mann-Whitney Rank-sum Test (P = 0.019) and testing parametrically using Students t-test (P = 0.022, ⌬ mean age = 4.7 years, 95% CI: 0.7-8.8 years); and (c) vs (a + b) (corresponding to genotypes containing the 1-bp deletion vs those that do not), Mann-Whitney Rank-sum Test (P = 0.034), Students t-test (P = 0.043).
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In the total sample: (a) vs (c), Mann-Whitney Rank-sum Test (P = 0.037), Students t-test (P = 0.080).
The same authors reported also that symptoms were more severe in males than in females, and that this gender difference disappeared after around 5 years. To what extent DDC might influence these specific parameters should be scrutinized in future studies of suitable patient samples. Moreover, several studies have reported that the early onset in males was particularly evident in paranoid schizophrenia, [22] [23] [24] and paranoid symptoms have been specifically related to increased dopaminergic activity on the basis of amphetamine-induced psychosis. 25, 26 It has been shown that amphetamine causes a reduction in DDC mRNA and 2-PE production. 27 This could be due to a homeostatic negative feedback mechanism since amphetamine is a structural analogue of 2-PE and is most likely acting as a 2-PE agonist, and DDC is the rate-limiting enzyme in the synthesis of 2-PE. 8 On this basis, it is tempting to hypothesize that DDC might be involved in the development of paranoid schizophrenia.
In conclusion, the results presented do not support that DDC should be of etiologic importance in schizophrenia as a whole. However, we have obtained evidence suggesting that DDC may possibly act as a modulator of age at disease onset in males, and that this effect seems to be dependent on specific haplotypebased genotypes comprising both DDC variants examined. However, more studies are needed to investigate this hypothesis. Likewise, to what extent this possible modulating effect relates to specific clinical subtypes or symptom dimensions remains to be clarified.
Materials and methods
Subjects
One hundred and seventy-three unrelated schizophrenic patients of Scottish decent and 204 ethnically matched controls were included in the study. Informed consent was obtained from all individuals prior to inclusion. All diagnoses were based on SADS-L interview 28 and used RDC 29 and DSM-IV criteria. All of the schizophrenic patients had a chronic course and all were taking medication on a long-term basis. Forty-five patients had a positive family history defined as a first or second degree relative with schizophrenia. One hundred and fifty-three cases (99 males and 54 females) gave reliable information with regard to age at disease onset defined as onset of first psychotic symptoms. As age at onset was not perfectly normally distributed, both non-parametric and parametric analyses were used. In the total sample the mean age at onset was 25.9 years, the harmonic mean was 23.2 years, and the median was 23 years. In male patients the same parameters were 25.0, 22.8 and 23 years, respectively, and in females they were 27.4, 24.0, and 24 years, respectively. The controls were from the Blood Transfusion Service, Edinburgh. They were screened to exclude people with serious chronic illness and those taking any form of medication apart from contraceptive pill and hormone replacement therapy. Genomic DNA was isolated from blood samples according to standard procedures.
Genotyping
Genotyping of the two DDC variants was performed essentially as described previously. 11 Briefly, a multiplex PCR amplification with radioactive 33 P end-labeled primers was carried out under standard conditions in the presence of 150 ng genomic DNA, 0.4 M of each of the 1-bp deletion primers, and 1.2 M of each of the 4-bp deletion primers. The primers for the 1-bp deletion variant were DDCprom-up (5Ј-GCACCCATCAACCAGAAGT-3Ј) and DDCprom-low 1del (5Ј-GCCTATCAGCATCTAAAACAT-3Ј) amplifying products of 118 bp and 117 bp. The primers for the 4-bp deletion variant were DDCprom-up4del (5Ј-GCTTCGGGGAGGCAGACAC-3Ј) and DDCprom-low (5Ј-GGATGAGGACAAAGAGCAGTA-3Ј) amplifying products of 143 bp and 139 bp. PCR products were heat denatured in 50% formamide for 5 min before separation on a 6% polyacrylamide/6 M urea gel. After vacuum drying the gel was autoradiographed for 5 days.
Statistical analysis
Allele, simple genotype, and haplotype-based genotype distributions were compared using the 2 test and Wilcoxon Rank-sum Test with correction for ties, the latter being the more powerful test in analyses of ordered contingency tables and consequently preferred in comparisons of particularly haplotype-based genotype distributions. Age at onset distributions were compared parametrically using Students t-test and non-parametrically using Mann-Whitney Rank-sum Test with correction for ties. The correlation between age at onset distributions in relation to haplotype-based genotypes was tested by linear regression analysis. Calculations of linkage disequilibrium were carried out using the EH program. 13 
